For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Deemed dividend | - | 932,246 | - | 0 |
| Tax benefit | - | - | - | 0 |
| Administration expenses (including noncash compensation expense of 11,581,251 and 52,853,115 for the nine months ended march 31, 2026 and 2025, respectively, and 5,351,136 and 52,838,115 for the three months ended march 31, 2026 and 2025, respectively | 6,219,644 | 3,628,173 | 4,598,574 | 3,585,351 |
| Occupancy expenses - related party | 10,917 | 6,600 | 14,789 | 6,373 |
| Research and development | 169,660 | 19,961 | 60,201 | 53,522 |
| Total operating expenses | 6,400,221 | 3,654,734 | 4,673,564 | 3,645,246 |
| Loss from operations | -6,400,221 | -3,654,734 | -4,673,564 | -3,645,246 |
| Interest expense | 38,270 | 58,955 | 305,649 | 254,542 |
| Interest income | 13 | 37 | 19 | 7 |
| Derivative expense | - | - | - | 238,584 |
| Change in fair value of derivative liabilities | -18,146 | 87,728 | -19,706 | 98,963 |
| Change in fair value of warrant liability | -182,517 | -593,710 | - | - |
| Other expense | 43,000 | 54,000 | - | - |
| Settlement expense | 90,000 | - | - | - |
| Gain (loss) on extinguishment of debt, net | -74,235 | 14,317 | 195,861 | -31,000 |
| Foreign currency transaction gain (loss) | 35,006 | -19,497 | -34,699 | -1,059 |
| Total other income (expense), net | 39,885 | 563,340 | -164,174 | -426,215 |
| Loss before taxes | -6,360,336 | -3,091,394 | -4,837,738 | -4,071,461 |
| Net loss | -6,360,336 | -3,091,394 | -4,837,738 | -4,071,461 |
| Net loss | -6,360,336 | -4,023,640 | - | -4,071,461 |
| Unrealized foreign currency translation loss (gain) | -93,349 | -7,846 | 17,044 | -145,640 |
| Total other comprehensive income (gain) | -93,349 | -7,846 | 17,044 | -145,640 |
| Total comprehensive loss | -6,453,685 | -4,031,486 | -4,820,694 | -4,217,101 |
| Basic EPS | -0.28 | -0.3 | -0.39 | -1.063 |
| Diluted EPS | -0.28 | -0.3 | -0.39 | -1.063 |
| Basic Average Shares | 22,427,486 | 13,360,358 | 12,331,526 | 3,968,176* |
| Diluted Average Shares | 22,427,486 | 13,360,358 | 12,331,526 | 3,968,176* |
Propanc Biopharma, Inc. (PPCB)
Propanc Biopharma, Inc. (PPCB)